Philip Wong

Academic title(s): 

Associate Professor of Medicine, McGill University

Philip Wong
Contact Information
Address: 

MUHC, Royal Victoria Hospital

1001 boul Decarie, Montreal, QC H4A 3J1

Position: 
Site Director, Division of Gastroenterology & Hepatology RVH Site
Degree(s): 

MSc, MD, FRCP

Fellowship Training: 
  • Fellowship training: Hepatology Fellowship. University of Manitoba, Winnipeg, Manitoba, September 2000 – June 2001
  • Transplant Hepatology, University of Toronto Multi-Organ Transplant Program, Toronto, Ontario, June – September 2001
  • Master of Science (MSc.), Epidemiology & Biostatistics (Thesis), McGill University, Montreal, Quebec

Thesis title: “Quality Of Life In Liver Transplant Patients:Responsiveness Of The SF-36, EQ-5D And GHQ-30

Supervisors: Nancy Mayo Ph.D (Epidemiology)

Alan Barkun MD, MSc. (Epidemiology)

Marc Deschenes MD

Awarded: May 31, 2005

Areas of expertise: 

General Hepatology and Liver transplantation, General Gastroenterology

Biography: 

Dr. Wong is from Saskatchewan, where he was a pharmacist before medical school, and completed training in Internal Medicine. From there, he did his GI training in Montreal at McGill University, with General Hepatology training in Winnipeg at the University of Manitoba, and then Liver Transplantation at the University of Toronto. A Master's degree in Epidemiology and Biostatistics followed at McGill University and after a 2 year stint on staff at the University of Toronto Multi-organ transplant program, he and his family returned to McGill in 2006, where he is an Associate Professor of Medicine, and Hepatologist-Gastroenterologist. He serves as the Site Director of the Department of Gastroenterology at the Royal Victoria Hospital. Dr. Wong's research interests include outcomes in liver transplantation, viral hepatitis, fatty liver and cirrhosis and its complications such as hepatic encephalopathy.

Selected publications: 

1. Accepted to European Radiology June 11, 2019: Ms. No. EURA-D-19-00299R1. "Prospective Comparison of Transient, Point Shear Wave, and Magnetic Resonance Elastography for Staging Liver Fibrosis". Authors: Thierry Lefebvre; Claire Wartelle-Bladou, MD; Philip Wong, MD MSc; Giada Sebastiani, MD; Jeanne-Marie Giard, MD MPH; Hélène Castel, MD; Jessica Murphy-Lavallée, MD; Damien Olivié, MD; André Ilinca; Marie-Pierre Sylvestre, PhD; Guillaume Gilbert, PhD; Zu-Hua Gao, MD PhD; Bich N. Nguyen, MD; Guy Cloutier, PhD Eng; An Tang, MD MSc

2. Tomaszewski M, Wong P. Stem Cell Therapy in the Elderly with Liver Disease. OBM Hepatol Gastroenterol 2019 Jan;3(1):16; doi:10.21926/obm.hg.1901013.

3. Benmassaoud A, Nitulescu R, Pembroke T, Halme AS, Ghali P, Deschenes M, Wong P, Klein MB, Sebastiani G. Liver-related events in HIV-infected persons with occult cirrhosis. Clin Infect Dis. 2018 Dec 18.

4. Nguyen H, Swain M, Wong P, Congly S. Published online December 2018 in CMAJ Open. cmajo 6:E575-E579; doi:10.9778/cmajo.20180024. “Canadian regulations and legal ramifications for hepatic encephalopathy: a descriptive analysis”.

5. Brahmania M, Renner EL, Coffin CS, Yoshida EM, Wong P, Zeman M, Shah H. Ann Hepatol. 2018 Dec 13;18(1):165-171. doi: 10.5604/01.3001.0012.7908. Choosing Wisely Canada-Top Five List in Hepatology: Official Position Statement of the Canadian Association for the Study of the Liver (CASL) and Choosing Wisely Canada (CWC)

6. Chiara Saroli Palumbo, Philip Wong. AME Med J 2018;3:73. doi: 10.21037/amj.2018.06.07. View article at: http://dx.doi.org/10.21037/amj.2018.06.07 What is the role of transplantation in the management of alcoholic liver disease?

7. Al-Judaibi B, Thomas B, Wong P, Benmassaoud A, Chen JH, Dokus MK, Hussaini T, Bilodeau M, Burak KW, Marotta P, Yoshida EM. Ann Hepatol. 2018 May-June;17(3):437-443. doi: 10.5604/01.3001.0011.7388. Epub 2018 Apr 9. Sofosbuvir-Based Therapy in the Pre-Liver Transplant Setting: The Canadian National Experience.

8. Benmassaoud A, Ghali P, Cox J, Wong P, Szabo J, Deschenes M, Osikowicz M, Lebouche B, Klein MB, Sebastiani G. PLoS One. 2018 Jan 30;13(1):e0191985. doi: 10.1371/journal.pone.0191985. eCollection 2018. Screening for nonalcoholic steatohepatitis by using cytokeratin 18 and transient elastography in HIV mono-infection.

9. Pembroke T, Deschenes M, Lebouché B, Benmassaoud A, Sewitch M, Ghali P, Wong P, Halme A, Vuille-Lessard E, Pexos C, Klein MB, Sebastiani G. J Hepatol. 2017 Oct;67(4):801-808. doi: 0.1016/j.jhep.2017.05.011. Epub 2017 May 18. Hepatic steatosis progresses faster in HIV mono-infected than HIV/HCV co-infected patients and is associated with liver fibrosis.

 

Location: 
MUHC, Royal Victoria Hospital
Back to top